Key result
This commentary details critical differences in assumptions and methodology regarding the use of resting peak alpha frequency as a biomarker for individual pain sensitivity.
Answers are grounded in this paper and cite their sources.
The authors provide a commentary detailing critical differences between their previous work and a recent study by Valentini et al. regarding peak alpha frequency as a biomarker for pain sensitivity.
The study by Valentini et al. (2022) observed that the peak alpha frequency (PAF) of participants became slower after they were exposed to painful, as well as non-painful but unpleasant stimuli. The authors interpreted this as a challenge to our previous studies which propose that the speed of resting PAF, independently of pain-induced changes to PAF, can be a reliable biomarker marker for gaging individual pain sensitivity. While investigations into the role that PAF plays in pain perception are timely, we have some concerns about the assumptions and methodology employed by Valentini et al. Moreover, we believe the authors here have also misrepresented some of our previous work. In the current commentary, we detail the critical differences between our respective studies, with the ultimate aim of guiding future investigations.
No takes yet. Share an insight, caveat, or question.
Mazaheri et al. (2022) conducted an editorial in Pain sensitivity. Peak alpha frequency (PAF) was evaluated. This commentary details critical differences in assumptions and methodology regarding the use of resting peak alpha frequency as a biomarker for individual pain sensitivity.
Synapse has enriched 10 related papers. Consider them for comparative context: